Identification of DDX60 as a Regulator of MHC-I Class Molecules in Colorectal Cancer

Immune checkpoint blockade (ICB) therapies induce durable responses in approximately 15% of colorectal cancer (CRC) patients who exhibit microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR). However, more than 80% of CRC patients do not respond to current immunotherapy. The ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Nina, Hu, Tuo, He, Chunbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775109/
https://www.ncbi.nlm.nih.gov/pubmed/36551849
http://dx.doi.org/10.3390/biomedicines10123092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775109/
https://www.ncbi.nlm.nih.gov/pubmed/36551849
http://dx.doi.org/10.3390/biomedicines10123092

Ejemplares similares